drugset / Trial / NCT07521046
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.
Timeline
- Start
- 2026-10
- Primary completion
- 2029-08
- Completion
- 2030-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ropeginterferon alfa-2b | Protein / enzyme biologic | — | Subcutaneous |
| Background | Ruxolitinib | Small molecule | — | — |